noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

The Office of the Governor of the[...]

Shapiro Administration Invests Nearly $54 Million in 50 Transportation[...]
Western Washington University

WWU’s Academic Advising and Student Achievement is now Academic[...]
NYSE Group Inc.

91 FR 52770 (8/14/26)

Healthcare

Lexaria Bioscience Corp.

08/17/2026 | Press release | Distributed by Public on 08/17/2026 10:38

Material Event (Form 8-K)

Item 8.01

Other Events

Cure of Nasdaq Bid Price Deficiency

On August 17, 2026, Lexaria Bioscience Corp. (the "Company") received a letter from the Hearings Advisor of The Nasdaq Stock Market ("Nasdaq") advising that the Nasdaq Listings Qualifications Staff had confirmed that the Company had regained compliance with the bid price requirement in Nasdaq Listing Rule 5550(a)(2). Consequently, the previously requested hearing has been cancelled and the Company's Common Stock will continue to be listed and trading on The Nasdaq Capital Market.

Lexaria Bioscience Corp. published this content on August 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 17, 2026 at 16:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]